CytomX Therapeutics, Inc. Form 4

July 13, 2017

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Number: January 31, Expires: 2005

OMB APPROVAL

3235-0287

0.5

Estimated average burden hours per

response...

OMB

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

Form 5

obligations

may continue.

See Instruction

(Print or Type Responses)

| 1. Name and Address of Reporting Person * THIRD ROCK VENTURES LP | | | 2. Issuer Name and Ticker or Trading Symbol CytomX Therapeutics, Inc. [CTMX] | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | |
|--|---|---------------|---|---|---|---|--|--|--|--|
| (Last) (First) (Middle) 29 NEWBURY STREET, 3RD FLOOR | | | 3. Date of Earliest Transaction (Month/Day/Year) 07/13/2017 | | | | DirectorX 10% Owner Officer (give title below) Other (specify below) | | | |
| (Street) BOSTON, MA 02116 | | | 4. If Amendment, Date Original Filed(Month/Day/Year) | | | | 6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person | | | |
| (City) | Table I - Non-Derivative Securities Acq | | | | | uired, Disposed of, or Beneficially Owned | | | | |
| 1.Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | Execution any | med on Date, if Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securitie or(A) or Disp (Instr. 3, 4 | osed o | of (D) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | |
| Common Stock | 07/13/2017 | | | <u>J(1)</u> | 850,000 | D | <u>(1)</u> | 4,320,348 | D (2) | |
| Common Stock | | | | | | | | 60,934 | D (3) | |
| Common Stock | | | | | | | | 89,292 | D (4) | |
| Common Stock | | | | | | | | 74,293 | D (5) | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Edgar Filing: CytomX Therapeutics, Inc. - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

> 9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of | 2. | 3. Transaction Date | 3A. Deemed | 4. | 5. | 6. Date Exerc | cisable and | 7. Title | e and | 8. Price of | |
|-------------|-------------|---------------------|--------------------|------------|------------|---------------|-------------|-----------|-------------------|-------------|--|
| Derivative | Conversion | (Month/Day/Year) | Execution Date, if | Transacti | onNumber | Expiration D | ate | Amour | nt of | Derivative | |
| Security | or Exercise | | any | Code | of | (Month/Day/ | Year) | Underl | ying | Security | |
| (Instr. 3) | Price of | | (Month/Day/Year) | (Instr. 8) | Derivative | e | | Securit | ties | (Instr. 5) | |
| | Derivative | | | | Securities | 1 | | (Instr. : | 3 and 4) | | |
| | Security | | | | Acquired | | | | | | |
| | | | | | (A) or | | | | | | |
| | | | | | Disposed | | | | | | |
| | | | | | of (D) | | | | | | |
| | | | | | (Instr. 3, | | | | | | |
| | | | | | 4, and 5) | | | | | | |
| | | | | | | | | | Amount | | |
| | | | | | | | | | Amount | | |
| | | | | | | Date | Expiration | | or Name la sur | | |
| | | | | | | Exercisable | e Date | | Number | | |
| | | | | C + V | (A) (D) | | | | of Cl | | |
| | | | | Code V | (A) (D) | | | i | Shares | | |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | | | | |
|--|---------------|-----------|---------|-------|--|--|--|
| | Director | 10% Owner | Officer | Other | | | |
| THIRD ROCK VENTURES LP 29 NEWBURY STREET, 3RD FLOOR BOSTON, MA 02116 | | X | | | | | |
| Third Rock Ventures GP, L.P. 29 NEWBURY STREET, 3RD FLOOR BOSTON, MA 02116 | | X | | | | | |
| TRV GP, LLC 29 NEWBURY STREET, 3RD FLOOR BOSTON, MA 02116 | | X | | | | | |
| LEVIN MARK J 29 NEWBURY STREET, 3RD FLOOR BOSTON, MA 02116 | | X | | | | | |
| STARR KEVIN P 29 NEWBURY STREET, 3RD FLOOR BOSTON, MA 02116 | | X | | | | | |
| TEPPER ROBERT I 29 NEWBURY STREET, 3RD FLOOR BOSTON, MA 02116 | | X | | | | | |

Reporting Owners 2

Signatures

In IV and a Citie Child Financial Office

| /s/ Kevin Gillis, Chief Financial Officer of TRV GP, LLC, general partner of Third Rock Ventures GP, L.P., general partner of Third Rock Ventures, L.P. | | | | | |
|---|------------|--|--|--|--|
| **Signature of Reporting Person | Date | | | | |
| /s/ Kevin Gillis, Chief Financial Officer of TRV GP, LLC, general partner of Third Rock Ventures GP, L.P. | 07/13/2017 | | | | |
| **Signature of Reporting Person | Date | | | | |
| /s/ Kevin Gillis, Chief Financial Officer of TRV GP, LLC | 07/13/2017 | | | | |
| **Signature of Reporting Person | Date | | | | |
| /s/ Kevin Gillis by power of attorney for Mark Levin | 07/13/2017 | | | | |
| **Signature of Reporting Person | Date | | | | |
| /s/ Kevin Gillis by power of attorney for Kevin Starr | 07/13/2017 | | | | |
| **Signature of Reporting Person | Date | | | | |
| /s/ Kevin Gillis by power of attorney for Robert I. Tepper | 07/13/2017 | | | | |
| | | | | | |

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

**Signature of Reporting Person

Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), TRV distributed on July 13, 2017, for no consideration, 850,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP, L.P. ("TRV GP"), the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro-rate

Date

- distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.
- These shares are directly held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
- (3) These shares are directly held by Starr. Includes Shares received in the distributions described in footnote (1) above.
- (4) These shares are directly held by Levin. Includes Shares received in the distributions described in footnote (1) above.
- (5) These shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3